

PIPETMAX®: Flexible Automated Workflow for Kinase Selectivity Profiling



APPLICATION NOTE AN1002

APPLICATION BENEFITS

Reliable and reproducible methods for screening kinase inhibitors are an important part of the drug discovery workflow.

SOLUTIONS

Automation of the Kinase Selectivity Profiling System with PIPETMAX, in conjunction with automated detection and data analysis methods, offers a streamlined workflow for single-point and dose-response evaluation of potential cancer therapies.

TRACY WORZELLA, HICHAM ZEGZOUTI, MATTHEW BUTZLER, JACQUELYN HENNEK, SAID GOUELI, MARK BRATZ, AND CRISTOPHER COWAN | Promega Corporation; Madison, WI, USA

SETH HANSON, KAREN KLEMAN, AND LAURA SIMDON | Gilson, Inc.; Middleton, WI, USA

ABSTRACT

Kinase inhibitors are an important class of therapeutics, and kinase profiling to confirm inhibitor selectivity and assess off-target activity is a critical step during the drug discovery process. However, performing these activities in the research lab is often cost-prohibitive. Further, manual pipetting into 384-well plates can be error prone and tedious. Here we demonstrate the use of pre-configured kinase enzyme profiling systems on affordable automated liquid handling and bioluminescence detection instrumentation, which enables researchers to quickly profile their compounds of interest on-site, generating reliable and reproducible data on demand and on their timeline.

INTRODUCTION

Protein kinases regulate key cellular functions including signal transduction, cell division, and apoptosis. This enzyme group constitutes one of the largest (>500) and most functionally diverse gene families and has been implicated in cancer and various diseases. Deregulation of kinases by small molecule inhibitors has become a standardized therapy treatment.¹

Kinase profiling is a necessary part of the drug discovery process in order to confirm that small molecule inhibitors are specific to the protein kinase of interest, and to determine whether the inhibitor demonstrates off-target activity. Optimizing kinase



Figure 1

Reaction assembly, detection, and data analysis are automatically conducted according to user-input parameters for single or dose-response testing of up to two kinase strips per plate.

IN COLLABORATION WITH:



reactions and maintaining a library of purified enzymes can be so arduous that labs choose to outsource their kinase profiling activities.

Here we report how a ready-to-use Kinase Selectivity Profiling System (KSPS) from Promega Corporation, combined with easy to use automation, signal detection, and data analysis (Figure 1) supports a streamlined workflow to enable quick and efficient in-house kinase inhibitor profiling.

MATERIALS AND METHODS

Enzymes and Reagents

Commercial KSPS kits containing 8-tube strips of kinases and substrates were obtained from Promega Corp. (Madison, WI) and used according to manufacturer's directions.² The ADP-Glo™ Kinase Assay³ (V6930, Promega) was used to quantify kinase activity. Stock solutions of inhibitor compounds were diluted to 1 mM in DMSO before use.

Automated Reaction Setup for Liquid Handling

Kinase enzyme reaction setup, including compound dilution and preparation of kinase working stock and ATP/substrate working stock, was carried out using a PIPETMAX® automated liquid handler (Gilson, Inc.; Middleton, WI). Reactions contained 1 µL of compound, 2 µL of kinase working stock and 2 µL of the corresponding ATP/substrate working stock. Addition of ADP-Glo and kinase detection reagent was also carried out using PIPETMAX. Negative controls (no compound and no compound/no kinase) were included on each plate.

Automated KSPS protocols for PIPETMAX (www.gilson.com) were developed and tested by Promega. Protocols were imported into TRILUTION® micro 2.0 software (Gilson). Kinase and substrate strip tubes were placed in a cold (-0°C) passive thermal block with metal overlay (Rack 496 PT, Gilson, Inc.). Compound serial dilution was performed in a Costar 3897 V-bottom 96-well plate. Reagents (compound diluent, ATP, 2.5x Kinase Buffer, ADP-Glo Reagent and Kinase Detection Reagent) were placed in a Costar 3897 V-bottom 96-well plate as directed by the protocol. Kinase assay reactions were assembled in a white low volume Corning 4512 384-well assay plate (Figure 2).





Figure 2

Schematic and photograph of PIPETMAX® bed layout for automated Kinase Selectivity Profiling Systems. Liquid handling steps are performed by PIPETMAX®, using the bed layout and labware indicated. Kinases and substrates/cofactor stocks are each provided in an 8-tube strip and placed in a cold block. One-step dilutions directly in these strips produce sufficient Kinase and ATP/Substrate Working stocks for 25 kinase reactions in a 384-well plate. After 1-hour incubation in the presence of inhibitor, kinase activity is quantified using the ADP-Glo™ Kinase Assay. The resulting luminescent signal is proportional to kinase activity.

1. Tip waste
2. DS200ST tips in tip adapter block
3. DSL10ST tips in tip adapter block
4. Empty
5. Test compounds in positions A1–D1 of a 96-well, V-bottom plate, Corning 3897
6. Strip tubes containing kinase enzyme (columns 1 and 2) and substrate (columns 3 and 4) in passive thermal block 496PT (chilled to 0°C)
7. DSL10ST tips in tip adapter block
8. 384-well assay plate, white, Corning 4512
9. Assay reagents in positions A1–H6 of 96-well, V-bottom plate, Corning 3897

Liquid handling was carried out on PIPETMAX with tips validated for use with 384-well plates (DS200ST and DSL10ST). Centrifugation, mixing, and detection were performed off-bed, while room temperature reaction incubations were performed either directly on the bed of PIPETMAX instrument or on an off-bed temperature-controlled heat block held at 25°C.

Detection and Data Analysis

After the final incubation, the assay plate was transferred to a GloMax® Discover plate reader (Promega) and luminescence data were collected via the Kinase Selectivity Profiling SMART Protocol. The Solver and Analyze functions within Microsoft® Excel® Macro-Enabled worksheets for the Kinase Selectivity Profiling System Inhibitor Dose Response and Single Dose Inhibition protocols were used for automated data analysis to graph the data, fit curves, and calculate IC50 values.⁴

RESULTS AND DISCUSSION

Screening of selective and off-target kinase inhibitor activity was easily streamlined in a general laboratory setting using pre-configured kinase reactions (KSPS) and automated liquid handling, detection, and analysis programs. Several products are available in this line; kinases are grouped either in single family strips or as a general panel representative of the human kinome for a broad kinase profile (Figure 3).

| TK-2 | TK-4 | CMGC-1 | STE-1 | General Panel | | |
|-------|-------|--------|------------|---------------|---------------|----------|
| ABL1 | c-MER | ERK2 | ASK1 | FGFR1 | CDK2/CyclinE1 | AKT1 |
| BRK | FGFR1 | GSK3b | HPK1 | JAK3 | GSK3b | PKCa |
| BTK | FGFR2 | JNK1 | MINK1 | LCK | p38a | ROCK1 |
| CSK | FGFR4 | JNK3 | MST1 | SYK | AMPK A1/B1/G2 | Aurora A |
| FYN A | FLT1 | p38a | NIK | MINK1 | CAMK4 | CK2a1 |
| LCK | FMS | p38b | PAK1/CDK42 | PAK1/CDK42 | CHK1 | IKKb |
| LYN B | MET | p38d | PAK3 | IRAK4 | DAPK1 | CK1a1 |
| SRC | RET | p38g | TNIK | TAK1-TAB1 | MAPKAPK2 | CK1g1 |

Figure 3

The Promega Kinase Selectivity Profiling Systems contain 8 kinase and substrate pairs that are grouped by family (e.g. TK, CMGC, and STE) or as a General Panel. The color coding corresponds to different kinase families. 17 different KSPS kinase strips are available in the Promega catalog, and custom combinations of enzymes can also be ordered.

For these experiments, the PIPETMAX® was used to perform all liquid handling steps. The user selects either the single-dose or dose-response protocol and enters in the variables within the TRILUTION® micro run software to define the volume ratios for compound serial dilution (if applicable), dictate the number of kinase and substrate strips to prepare for the run, and guide reaction setup in the assay plate. Reactions are prepared according to templates that are pre-configured for the multimode plate reader (GloMax, Promega Corporation) and Smart Protocol data analysis files.

For these experiments, the PIPETMAX was used to perform all liquid handling steps. The user selects either the single-dose or dose-response protocol and enters in the variables within the TRILUTION micro run software to define the volume ratios for compound serial dilution (if applicable), dictate the number of kinase and substrate strips to prepare for the run, and guide reaction setup in the assay plate. Reactions are prepared according to templates that are pre-configured for the multimode plate reader (GloMax, Promega Corporation) and Smart Protocol data analysis files.


A single point selectivity screen was performed with nine test compounds (1µM) and 24 unique kinases in one 384-well plate using automation and three KSPS general kinase panels. As shown in Table 1, staurosporine ubiquitously inhibited several kinases, whereas VX-702 and tofacitinib were selective in inhibiting p38α and JAK3, respectively. Ponatinib shows expected on-target inhibition of the Abl-associated LCK and FGFR tyrosine kinases, but unexpected off-target inhibition of p38α. Subsequent dose-response experiments with ponatinib verified potency for tyrosine kinases from KSPS: TK-2 and TK-4 and confirmed off-target effects with KSPS: CMGC-1 kinases (data not shown).

Table 1

Single-dose inhibitor profile (9 compounds) against three KSPS general panels (24 total kinases). The amount of enzyme activity remaining (%) following treatment with 1 μ M compound is reported. Boxes highlighted in red represent >80% inhibition.

| | | Bosutinib | Imatinib | Ponatinib | Sunitinib | Tofacitinib | SU6656 | VX-702 | Kenpaullone | Staurosporine |
|------|----------------|-----------|----------|-----------|-----------|-------------|--------|--------|-------------|---------------|
| GP-1 | FGFR1 | 39 | 82 | 4 | 22 | 71 | 29 | 81 | 77 | 2 |
| | JAK3 | 58 | 98 | 7 | 68 | 0 | 82 | 95 | 95 | -1 |
| | LCK | 0 | 69 | 0 | 33 | 99 | 57 | 107 | 75 | 1 |
| | SYK | 15 | 85 | 97 | 55 | 87 | 60 | 89 | 39 | -2 |
| | MINK1 | 4 | 101 | 65 | 42 | 109 | 100 | 85 | 43 | 1 |
| | PAK1/CDC42 | 69 | 103 | 125 | 104 | 103 | 108 | 92 | 98 | 32 |
| | IRAK4 | 42 | 95 | 99 | 28 | 106 | 54 | 106 | 97 | 2 |
| | TAK1-TAB1 | 90 | 102 | 35 | 30 | 109 | 101 | 108 | 89 | 5 |
| GP-2 | CDK2/CyclinE1 | 94 | 101 | 86 | 93 | 93 | 98 | 95 | 38 | 2 |
| | GSK3 β | 86 | 90 | 88 | 74 | 86 | 88 | 86 | 5 | 2 |
| | p38 α | 48 | 92 | 1 | 95 | 80 | 95 | 0 | 97 | 60 |
| | AMPK A1/B1/G2 | 53 | 103 | 82 | 7 | 77 | 21 | 88 | 82 | 1 |
| | CAMK4 | 80 | 101 | 96 | 25 | 94 | 101 | 93 | 96 | 3 |
| | CHK1 | 75 | 109 | 105 | 26 | 94 | 102 | 92 | 94 | 0 |
| | DAPK1 | 102 | 102 | 101 | 73 | 100 | 105 | 98 | 101 | 4 |
| | MAPKAPK2 | 85 | 87 | 89 | 84 | 87 | 85 | 88 | 85 | 26 |
| GP-3 | AKT1 | 99 | 99 | 93 | 88 | 103 | 97 | 101 | 100 | 0 |
| | PKC α | 78 | 102 | 94 | 85 | 62 | 92 | 78 | 101 | 1 |
| | ROCK1 | 68 | 96 | 93 | 58 | 95 | 78 | 87 | 50 | 1 |
| | Aurora A | 100 | 103 | 105 | 89 | 82 | 40 | 107 | 101 | 4 |
| | CK2 α 1 | 98 | 97 | 100 | 94 | 103 | 103 | 102 | 85 | 87 |
| | IKK β | 94 | 95 | 60 | 89 | 86 | 88 | 83 | 96 | 27 |
| | CK1 α 1 | 84 | 96 | 99 | 60 | 89 | 97 | 88 | 98 | 81 |
| | CK1 γ 1 | 101 | 94 | 94 | 50 | 93 | 97 | 94 | 98 | 88 |

Likewise, bosutinib, an Src family kinase inhibitor, shows expected on-target inhibition of the LCK tyrosine kinase, but unexpected off-target inhibition of MINK1.⁵ The specificity of bosutinib was further investigated in a dose-response profiling experiment with MINK1 and other like family kinases. PIPETMAX performed a 10-point serial 1:4 titration of bosutinib, added the diluted KSPS reagents: STE-1 kinases/substrates and dispensed ATP to start the kinase reaction. After 60 min at room temperature, the ADP-Glo™ reagents were added to measure the % activity. The results showed potent inhibition against TNIK (IC₅₀ = 3nM), HPK (IC₅₀ = 4nM), MINK1 (IC₅₀ = 29nM), MST1 (IC₅₀ = 56nM), and to a lesser extent PAK/CDC42, PAK3 and NIK (Figure 4).

**Figure 4**

Dose response experiments were performed to evaluate bosutinib potency against the kinases in the STE-1 family. Reactions were performed in duplicate.

To assess reproducibility of the assay, kinase reactions were assembled on two independent PIPETMAX instruments using the same experimental parameters. Serial dilution of bosutinib, preparation of kinase and substrate/ATP working stocks, assembly of kinase activity reactions, and dispensing of ADP-Glo™ and kinase detection reagent were carried out using a Gilson PIPETMAX automated liquid handler. As shown in Figure 5, this dose-response experiment with bosutinib and STE-1 kinase strip, with a dilution factor of 4, yielded very reproducible inhibition data. An example of MINK1 from the STE-1 KSPS is shown in Figure 5.




Figure 5

Reproducibility of MINK1 inhibition profile. The graph shows data from duplicate reactions assembled on two independent PIPETMAX® liquid handlers (i.e. four reactions per condition).

The Kinase Selectivity Profiling Systems come ready-to-use and no assay optimization is required. Complete automation, from compound dilution and addition through detection reagent dispensing, was easily and reliably achieved with PIPETMAX. These pre-configured kinase assays, coupled with automated pipetting, detection, and analysis methods, provide a streamlined workflow for convenient, in-house, single-point and dose-response kinase profiling.

Gilson, Inc.

3000 Parmenter Street • PO Box 620027 • Middleton, WI 53562 USA
Tel: 608-836-1551 or 800-445-7661 • F 608-831-4451

Gilson S.A.S.

19, avenue des Entrepreneurs BP 145, F-95400 Villiers-le-Bel, France
T +33 (0) 1 34 29 50 00 • F +33 (0) 1 34 29 50 20

REFERENCES

1. Gross S., Rahal R., Stransky N., et al. Targeting cancer with kinase inhibitors. *J Clin Invest.*, 125, 1780-1789 (2015).
2. Promega Technical Manual TM421 (2015). Download at www.promega.com.
3. Zegzouti, H., Zdanovskaia M, Hsiao K, Goueli SA. ADP-Glo: A bioluminescent and homogeneous ADP monitoring assay for kinases. *Assay Drug Dev. Technol.*, 7, 560-572 (2009).
4. Kinase Selectivity Profiling Systems Data Analysis Worksheets. Download at www.promega.com.
5. Vultur, A., Buettner, R., Kowolik, C., et al. SKI-606 (bosutinib), a novel Src kinase inhibitor, suppresses migration and invasion of human breast cancer cells. *Mol. Cancer. Ther.* 7, 1185 - 1194 (2008).

SUMMARY

- Kinase inhibitors represent an important focus for potential cancer therapies.
- This application note demonstrates a ready to use, validated system for the systematic profiling of kinase inhibitors.
- PIPETMAX® automates the assay setup of the Promega Kinase Selectivity Profiling System for both single point screening and dose response evaluation.
- The GloMax® Discover plate reader simplifies data collection and analysis with the Kinase Selectivity Profiling SMART Protocols.

Trademarks

All product and company names are trademarks™ or registered® trademarks of their respective holders. Use of the trademark(s) in this document does not imply any affiliation with or endorsements by the trademark holder(s).

GloMax is a registered trademark of Promega

APD-Glo is a trademark of Promega

Microsoft and Excel are registered trademarks of the Microsoft Corporation in the United States and/or other countries